9th Jul 2019 13:37
(Alliance News) - Renalytix AI PLC on Tuesday reported positive interim analysis of data from the KidneyIntelX expanded validation study.
The clinical diagnostics company said the results showed that the KidneyIntelX has met or exceeded required performance targets for identifying those patients experiencing rapid kidney function decline in patients with type 2 diabetes and existing chronic kidney disease.
Renalytix said this data will support the ongoing regulatory process with the US Food & Drug Administration.
"We have now completed the complex process of integrating electronic health record data and our proprietary blood biomarker measurements from over 3,000 patients with type 2 diabetes," said Chief Technology Officer Fergus Fleming.
Renalytix intends to provide further updates on this process in the near term as appropriate, it said.
The stock was trading 4.0% higher on Tuesday at 338.00 pence a share in London.
Related Shares:
Renalytix Plc